Pharmabiz
 

Piramal Pharma Solutions bags CPhI Worldwide award

Our Bureau, MumbaiWednesday, October 25, 2017, 16:45 Hrs  [IST]

Piramal Pharma Solutions (PPS) was recognized as the winner of the 'Regulatory Procedures and Compliance' award at the prestigious CPhI Pharma Awards (2017) at the Intercontinental Hotel - Frankfurt, Germany. PPS competed with several of its global peers in the category.

Regulatory excellence is an area that is fundamental to the needs of our end customers, and the CPhI Pharma Awards are among the most coveted recognitions in the pharmaceutical industry. It celebrates thinkers and creators that break new ground, recognizing companies that drive the industry forward. With over 200 entries submitted in 19 different award categories, the CPhI Pharma Awards serve as a great barometer for industry excellence.

PPS is a leading global Contract Development and Manufacturing Organization (CDMO), with 12 locations in North America, Europe, and Asia, driving solutions for our customers, from discovery through commercialization. With a stellar track record that includes 34 launched products for customers, Piramal is now a 'partner of choice' for leading pharmaceutical and biotech firms in North America and Europe.

PPS' global capabilities include, Discovery Chemistry Support, Drug Substance Development and Manufacturing, Formulation Development through Commercialization, and clinical trial Supplies. Further, Piramal is a leader in developing and manufacturing Antibody Drug Conjugates (ADCs) from early development to launch. With a commitment to investing capital that meet our customers' future needs, a robust balance sheet, a strong management team, and a focus on customer centricity, PPS expects to continue to make a positive impact in human life for years to come.

CPhI Worldwide announced the winners of the 2017 CPhI Pharma Awards during a live gala dinner at the Intercontinental Hotel in Frankfurt. The awards celebrate and recognise pharmaceutical excellence, and strongly encourage companies that are committed to participate in the growing and evolving pharma industry.

In the ‘API Development’ category, the winner was Cambrex’s new, efficient synthesis of Ospemifene – which uses standard plant equipment and requires only two synthetic steps and one recrystallization, minimising waste and use of solvents.

Orbis Biosciences was given the ‘Formulation’ award for Orbis’ Optimum technology for oral drug products, which has the ability to create microcapsules with uniform shell thickness that contain pH responsive polymers for targeted delivery approaches for a broad range of active ingredients.

The ‘Excipients’ award has been presented to Colorcon for the Opadry QX, Quick and Flexible film coating. This product reduces preparation and production times, and ensures coating process efficiency and cost savings in all types of equipment, from traditional to continuous coating.

MJR PharmJet triumphed in the ‘Manufacturing Technology and Equipment’ category with the MicroJet Reactor technology, making it possible to produce of a wide range of particle sizes with combination of process parameters from 10 nm up to 20 µm.

In the category of ‘Bioprocessing’, Capsugel was successful with the Modular Automated Sampling Technology (MAST™) platform. MAST™ allows direct transfer of aseptically collected bioreactor samples to analytical devices, providing rapid, reliable data for superior bioprocess guidance.

CryoBio was granted the ‘Analysis, Testing, and Quality Control’ award for FlexiQuot, the world’s first dividable cryotube, which is revolutionising sample collection, storage and handling for liquid sample long term storage products.

Out of over 20 entries, Perlen was triumphant in the ‘Drug Delivery Devices’ category with its Single Use Inhaler (DPI) Perlamed-BLISTair (R).

The SideActuationDevice by Aero Pump won in the category ‘Packaging’ for its metered dosing pump, which ensures a strict dose accuracy over the whole life cycle of the product, only one defined drop per actuation, independent of the filling volume of the bottle.

The award for ‘Supply Chain, Logistics, and Distribution’ has been given to TraceLink for its series of real-time information sharing applications to connect the entire pharmaceutical supply chain on an interoperable network, facilitating a new era of real-time information sharing that will transform how the industry provides care to patients.


Crystec was granted the ‘Contract Services and Outsourcing’ award for its modified supercritical anti-solvent (mSAS) technology, a single-step, high yielding and readily scalable process to generate dry, free flowing particles, designed to meet a target product profile and optimise drug delivery.

Pharma5 achieved the award for ‘Corporate Social Responsibility’ for its Hepatitis project in Morocco. After the success of the new generation drug against Hepatitis C, Pharma5 is now launching the first treatment of Hepatitis B in Morocco.

Richard Chin, MD, the founder and CEO of Kindred Biosciences, has been awarded the prestigious ‘CEO of the Year’ award. KindredBio is a biopharmaceutical company focused on saving and improving the lives of pets.

BenevolentAI, the global leader in the development and application of AI for scientific innovation, has been granted the award for ‘Pharma Company of the Year (SME)’. BenevolentAI has proven its technology by applying it to human biology and has made significant progress in accelerating drug development, particularly in reference to ALS.

AptarGroup’s internal Landfill Free certification program has been selected as the winner of the ‘Sustainability Initiative of the Year’ category for promoting process efficiencies and the conservation of natural resources in a global setting.

RACHANA OVERSEAS INC. was awarded in the ‘Excellence in Pharma: Export Promotion’ category, while Pronova emerged as the winner of the ‘OTC’ category.

Within ‘Patient Centricity’, ERT was victorious with the innovative digital health network, TARGET My Hives, which helps patients actively take control of their condition through stronger engagement with physicians, patient association groups and others affected by chronic urticaria.

Recognised for its expertise in device R&D, Biocorp received the ‘IT, mHealth & Digitilisation’ award. Biocorp has incorporated software develop.

 
[Close]